Thromb Haemost 1999; 82(06): 1627-1633
DOI: 10.1055/s-0037-1614890
Rapid Communication
Schattauer GmbH

In Vitro Characterisation of Two Naturally Occurring Mutations in the Thrombin-sensitive Region of Anticoagulant Protein S

Tusar K. Giri
1   From the Department of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
,
Pablo García de Frutos
1   From the Department of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
,
Tomio Yamazaki
1   From the Department of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
,
Bruno O. Villoutreix
1   From the Department of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
,
Björn Dahlbäck
1   From the Department of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
› Author Affiliations

Further Information

Publication History

Received 17 May 1999

Accepted after revision 27 July 1999

Publication Date:
10 December 2017 (online)

Summary

The molecular consequences of two naturally occurring mutations in the thrombin-sensitive region of protein S were investigated using a combination of recombinant protein expression, functional analysis and molecular modelling. Both mutations (R49H and R70S) have been found in thrombosis patients diagnosed as having type I protein S deficiency. Molecular modelling analysis suggested the R49H substitution not to disrupt the structure of thrombin-sensitive region, whereas the R70S substitution could affect the 3D structure mildly. To elucidate the molecular consequences of these substitutions experimentally, site directed mutagenesis of protein S cDNA and expression in mammalian cells created the two mutants. The secretion profiles and functional anticoagulant activities of the protein S mutants were characterised. Secretion of the R49H mutant was similar to that of wild type protein S, whereas the R70S mutant showed moderately decreased expression. Neither of the mutants showed any major functional defects as cofactors to activated protein C (APC) in an APTT-based assay or in degradation of factor Va. However, both mutants demonstrated decreased activity in a factor VIIIa degradation assay, which in addition to APC and protein S also included factor V as synergistic APC cofactor. In conclusion, the R49H substitution did not produce a quantitative abnormality in vitro, raising doubts as to whether it caused the type I deficiency. In contrast, the experimental data obtained for the R70S mutant agrees well with the observed type I deficiency. Our study illustrates that in vitro experimental characterisation together with computer-based structural analysis are useful tools in the analysis of the relationship between naturally occurring mutations and clinical phenotypes.

 
  • References

  • 1 Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
  • 2 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
  • 3 Dahlbäck B. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995; 125: 566-71.
  • 4 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of Factor V at Arg 506 by Activated Protein C and the Expression of Anticoagulant Activity of Factor V. Blood 1999; 93: 2552-8.
  • 5 Hackeng TM, van ’t Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
  • 6 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
  • 7 van Wijnen M, van ’t Veer C, Meijers JC, Bertina RM, Bouma BN. A plasma coagulation assay for an activated protein C-dependent anticoagulant activity of protein S. Thromb Haemost 1998; 80: 930-5.
  • 8 Mahasandana C, Suvatte V, Marlar RA, Manco Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335: 61-2.
  • 9 Gandrille S, Borgel D, Ireland H, Lane DA, Simmonds R, Reitsma PH, Mannhalter C, Pabinger I, Saito H, Suzuki K, Formstone C, Cooper DN, Espinosa Y, Sala N, Bernardi F, Aiach M. Protein S deficiency: A database of mutations. Thromb Haemost 1997; 77: 1201-14.
  • 10 Simmonds RE, Ireland H, Lane DA, Zöller B, García de Frutos P, Dahlbäck B. Clarification of the Risk for Venous Thrombosis Associated with Hereditary Protein S Deficiency by Investigation of a Large Kindred with a Characterized Gene Defect. Ann Int Med 1998; 128: 8-14.
  • 11 Lundwall Å, Dackowksi W, Cohen E, Shaffer M, Mahr A, Dahlbäck B, Stenflo J, Wydro R. Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc Natl Acad Sci USA 1986; 83: 6716-20.
  • 12 Dahlbäck B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265: 8127-35.
  • 13 He X, Shen L, Dahlbäck B. Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-Sdefining modules important for the species specificity of the activated protein C cofactor activity. Eur J Biochem 1995; 227: 433-40.
  • 14 He X, Shen L, Villoutreix BO, Dahlbäck B. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin-K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998; 273: 27449-58.
  • 15 Stenberg Y, Drakenberg T, Dahlbäck B, Stenflo J. Characterization of recombinant epidermal growth factor (EGF)-like modules from vitamin-K-dependent protein S expressed in Spodoptera cells. Eur J Biochem 1998; 251: 558-64.
  • 16 Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 1992; 79: 3202-11.
  • 17 García de Frutos P, Alim RIM, Härdig Y, Zöller B, Dahlbäck B. Differential regulation of α and β chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-22.
  • 18 Criado-García O, Sánchez-Corral P, Rodríguez de Córdoba S. Isoforms of human C4b-binding protein. II.Differential modulation of the C4BPA and C4BPB genes by acute-phase cytokines. J Immunol 1995; 155: 4037-43.
  • 19 Criado-García O, González-Rubio C, López-Trascasa M, Pascual-Salcedo D, Munuera L, Rodríguez de Córdoba S. Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Haemostasis 1997; 27: 25-34.
  • 20 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-27.
  • 21 Zöller B, García de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85: 3524-31.
  • 22 Simmonds RE, Zöller B, Ireland H, Thompson E, García de Frutos P, Dahlbäck B, Lane DA. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of Type I and Type III plasma phenotypes. Blood 1997; 89: 4364-70.
  • 23 Yamazaki T, Katsumi A, Kagami K, Okamoto Y, Sugiura I, Hamaguchi M, Kojima T, Takamatsu J, Saito H. Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Blood 1996; 87: 4643-50.
  • 24 Gandrille S, Borgel D, Eschwege-Gufflet V, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sie P, Toulon P, Aiach M. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85: 130-8.
  • 25 Borgel D, Duchemin J, Alhenc-gelas M, Matheron C, Aiach M, Gandrille S. Molecular basis for protein S hereditary deficiency: genetic defect observed in 118 patients with type I and type IIa deficiencies. J Lab Clin Med 1996; 128: 218-27.
  • 26 Dahlbäck B, Lundwall Å, Stenflo J. Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S. J Biol Chem 1986; 261: 5111-5.
  • 27 Chang GTG, Aaldering L, Hackeng TM, Reitsma PH, Bertina RM, Bouma BN. Construction and characterization of thrombin-resistant variants of recombinant human protein S. Thromb Haemost 1994; 72: 693-7.
  • 28 Suzuki K, Nishioka J, Hashimoto S. Regulation of activated protein C by thrombin-modified protein S. J Biochem (Tokyo) 1983; 94: 699-705.
  • 29 Giri TK, Villoutreix BO, Wallqvist A, Dahlbäck B, García de Frutos P. Topological studies of the amino terminal modules of vitamin-K-dependent protein S using monoclonal antibody epitope mapping and molecular modeling. Thromb Haemost 1998; 80: 798-804.
  • 30 Villoutreix BO, Teleman O, Dahlbäck B. A theoretical model for the Gla-TSR-EGF-1 region og the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. J Computor-aided Mol Design 1997; 11: 293-394.
  • 31 Dahlbäck B, Stenflo J. Binding of bovine coagulation factor Xa to platelets. Biochemistry 1978; 17: 4938-45.
  • 32 Dahlbäck B. Purification of human C4b-binding protein and formation of its complex with vitamin-K-dependent protein S. Biochem J 1983; 209: 837-46.
  • 33 Whitt M. Liposome-mediated transfection. In Current Protocols in Molecular Biology. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. eds. Cambridge: Wiley; 1991: 9.4.1-4.
  • 34 Katsumi A, Senda T, Yamashita Y, Yamazaki T, Hamaguchi M, Kojima T, Kobayashi S, Saito H. Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Blood 1996; 87: 4164-75.
  • 35 Giri TK, Hillarp A, Härdig Y, Zöller B, Dahlbäck B. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79: 767-72.
  • 36 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
  • 37 Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa – factor IXa complex. – species specific interactions of components of the protein C anticoagulant system. Thromb Haemost 1997; 78: 1030-6.
  • 38 Van Wijnen M, Stam JG, Chang GT, Meijers JC, Reitsma PH, Bertina RM, Bouma BN. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J 1998; 330: 389-96.
  • 39 Nyberg P, Dahlbäck B, García de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Letters 1998; 433: 28-32.